Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
In the Literature
Updated USPSTF Cervical Cancer Screening Recommendations
In the Literature
July 2012, Vol 3, No 5
Cervical cancer remains an important public health issue. The US Preventive Services Task Force (USPSTF) has issued an update to its 2003 cervical cancer screening recommendations based on current evidence (Moyer VA, on behalf of the USPSTF.
Ann Intern Med
. 2012;156:880-891).
Read Article
Anti–PD-1/PD-L1 Antibodies Show Promising Antitumor Activity in Several Cancers
In the Literature
July 2012, Vol 3, No 5
Results from two phase 1 clinical trials—one evaluating an anti–PD-1 antibody (Topalian SL, et al.
N Engl J Med
. 2012; 366:2443-2454) and the second evaluating an anti–PD-1 ligand (PD-L1) antibody (Brahmer JR, et al.
N Engl J Med
. 2012;366:2455-2465)—suggest that targeting the PD-1/PD-L1 pathway may be beneficial in treating certain types of solid tumors, including advanced melanoma, non–small-cell lung cancer (NSCLC), and renal-cell cancer.
Read Article
Regorafenib Active in Advanced GIST after Failing Standard Therapy
In the Literature
July 2012, Vol 3, No 5
New data suggest that regorafenib, a unique inhibitor of several kinase-associated cancers, has a wide-range activity in this patient population (George S, et al.
J Clin Oncol
. 2012;30:2401-2407).
Read Article
High Response Rate with Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
In the Literature
July 2012, Vol 3, No 5
Newly reported results of a phase 2 clinical trial have shown that treatment with the antibody-drug conjugate brentuximab vedotin achieves high response rates in patients with relapsed or refractory HL whose disease has progressed even after receiving autologous stem-cell transplant (auto-SCT) salvage therapy (Younes A, et al.
J Clin Oncol
. 2012;30:2183-2189).
Read Article
Ipilimumab-GVAX Combination Safe for Metastatic Castration-Resistant Prostate Cancer
In the Literature
June 2012, Vol 3, No 4
A combination of ipilimumab and the granulocyte-macrophage colonystimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) was feasible and tolerable in an openlabel phase 1 study in men with metastatic castration-resistant prostate cancer (van den Eertwegh AJM, et al.
Lancet Oncol
. 2012;13:509-517).
Read Article
Navitoclax Shows Limited Clinical Activity in SCLC, but Findings Point to Potential New Biomarkers
In the Literature
June 2012, Vol 3, No 4
When oral navitoclax (ABT-263) was evaluated in an open-label, phase 2 study in adult patients with recurrent and progressive small-cell lung cancer (SCLC) who had received at least 1 prior therapy, this Bcl-2 inhibitor showed only limited activity (Rudin CM, et al.
Clin Cancer Res
. 2012;18;1-7).
Read Article
Phased Ipilimumab Improves PFS and OS in NSCLC
In the Literature
June 2012, Vol 3, No 4
Ipilimumab—added in a phased regimen to paclitaxel and carboplatin chemotherapy—increased progressionfree survival (PFS) and immune-related PFS in a randomized, double-blind, international, phase 2 study of previously untreated adult patients with non–small-cell lung cancer (NSCLC).
Read Article
Inotuzumab Ozogamicin Shows High Response Rate in Refractory/Relapsed ALL
In the Literature
June 2012, Vol 3, No 4
In a single-arm, phase 2 study, inotuzumab ozogamicin, a CD22 monoclonal antibody conjugate, showed potential utility as a monotherapy that may improve the often poor prognosis for patients with refractory or relapsed acute lymphocytic leukemia (ALL; Kantarjian H, et al.
Lancet Oncol
. 2012;13:403-411).
Read Article
New Reimbursement Policies Needed to Align Payment with Cancer Care Outcomes
In the Literature
June 2012, Vol 3, No 4
Current reimbursement policies for cancer chemotherapies do not ensure that the value and cost of therapies are commensurate with outcomes.
Read Article
Patients with Cancer Willing to Pay More for Unproven, but Promising, Therapies
In the Literature
June 2012, Vol 3, No 4
Assessments of the value of cancer therapies have been based on the assumption that stakeholders care most about average or median gain in survival or quality-adjusted survival.
Read Article
Page 10 of 13
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma